DENVER, Colo., Apr 24, 2024 (247marketnews.com)- HOOKIPA Pharma Inc. (NASDAQ:HOOK) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, for the treatment of KRAS-mutated cancers, triggering a final $10 million milestone payment from Roche.

"We are proud to have another IND cleared for a potentially powerful oncology program. Our HB-700 program targets five KRAS-mutations found in multiple cancer indications with a single product candidate," commented Joern Aldag, Chief Executive Officer at HOOKIPA. "Importantly, the submission of the IND results in us receiving a final $10 million milestone payment. We continue to define our clinical development strategy which includes the possibility of collaboration or partnership for this program."

The post HOOKIPA Pharma Receives FDA Clearance of its IND Application for HB-700 for the Treatment of KRAS-Mutated Cancers appeared first on 24/7 MarketNews.

COMTEX_451345551/2900/2024-04-24T11:16:24